Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection

Md M N Azim1,2, Sujay Kumar Bhajan3, Jun Hong Park1

  • 1Department of Physiology, College of Veterinary Medicine, Jeonbuk National University, Iksan 54596, Republic of Korea.

Insights

Three-dimensional organoid technology creates patient-specific tumor models for precise cancer drug screening and personalized therapy. These advanced models show high predictive accuracy, paving the way for next-generation cancer research and treatment.

Area of Science:

  • Biomedical Engineering
  • Oncology
  • Stem Cell Biology

Background:

  • Cancer research urgently needs better preclinical models beyond 2D cultures and animal systems.
  • Three-dimensional (3D) organoid technology offers patient-specific mini-organ models that mimic primary tumors.
  • Organoids preserve key stem cell pathways (Wnt, Notch, Hippo) for disease modeling and drug screening.

Purpose of the Study:

  • To review organoid systems, including patient-derived organoids (PDOs) and induced pluripotent stem cell (iPSC)-derived organoids, as 'avatars' for personalized cancer therapeutics.
  • To highlight the role of organoids in functional precision medicine, citing >90% predictive accuracy in clinical studies.
  • To discuss organoids' potential in regenerative oncology for targeting cancer stem cells (CSCs) and enhancing tissue repair.

Main Methods:

  • Review of patient-derived organoids (PDOs) and induced pluripotent stem cell (iPSC)-derived organoids.
  • Analysis of organoid applications in disease modeling, high-throughput drug screening, and regenerative oncology.
  • Examination of advancements in organoid-on-a-chip, 3D bioprinting, and AI for addressing challenges like vascularization and immune integration.

Main Results:

  • Organoids accurately recapitulate tumor genetics, phenotype, and architecture.
  • Organoids demonstrate high predictive accuracy (>90%) in clinical studies, validating their use in precision medicine.
  • Emerging technologies like organoid-on-a-chip and AI integration are enhancing organoid capabilities.

Conclusions:

  • Organoids provide a fully humanized platform for preclinical cancer modeling and clinical applications.
  • Organoid technology is poised to advance personalized cancer therapeutics with improved predictive and translational power.
  • Standardized, GMP-compliant platforms and regulatory initiatives support the integration of organoids into cancer research and therapy.